1 Min Read
June 1 (Reuters) - Lion Biotechnologies Inc:
* Lion Biotechnologies announces first patient dosed in phase 2 trial of ln-145 for head and neck cancer Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.